NG12-2

The drug 'NG12-2' was not specifically identified in the available search results as a distinct drug or program. However, VasoDynamics is developing a technology platform with several product pipelines aimed at protecting skin, mucosa, and hair for cancer patients undergoing treatment. One such program is 'NG12', focused on the prevention of radiation-induced dermatitis. 'NG12-1', a product within this program, has completed a Phase IIa investigator-initiated trial (NCT01263366) for the reduction and prevention of severe radiodermatitis. Radiation-induced dermatitis is a common complication of radiotherapy, affecting a high percentage of treated patients and ranging in severity from redness to ulceration. The company's proprietary technology platform utilizes the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment while facilitating anti-cancer therapy efficacy.